期刊
GEBURTSHILFE UND FRAUENHEILKUNDE
卷 81, 期 4, 页码 469-480出版社
GEORG THIEME VERLAG KG
DOI: 10.1055/a-1397-7170
关键词
early breast cancer; therapy; prognosis; immune therapy; digital medicine
资金
- Pfizer
- Hexal
- Celgene
- Daiichi Sankyo
- Merrimack
- Eisai
- AstraZeneca
- Novartis
Recent years have seen significant progress in new therapeutic approaches to breast cancer, particularly in patients with HER2-positive and HER2-negative/HR+ breast cancer. Novel therapies, including targeted treatments and drug inhibitors, are showing promise in ongoing clinical trials.
In recent years, significant progress has been made in new therapeutic approaches to breast cancer, particularly in patients with HER2-positive and HER2-negative/hormone receptor-positive (HR+) breast cancer. In the case of HER2-positive tumours, these approaches have included, in particular, treatment with pertuzumab, T-DM1, neratinib and, soon, also tucatinib and trastuzumab deruxtecan ( neither of which has yet been authorised in Europe). In patients with HER2-/HR+ breast cancer, CDK4/6 inhibitors and the PIK3CA inhibitor alpelisib are of particular importance. Further novel therapies, such as Akt kinase inhibitors and oral SERDs (selective estrogen receptor down regulators), are already being investigated in ongoing clinical trials. These therapeutic agents are not only being introduced into curative, (neo-)adjuvant therapeutic settings for HER2-positive tumours; a first favourable study on abemaciclib as an adjuvant therapy has now also been published. In patients with triple-negative breast cancer, after many years of negative study results with the Trop-2 antibody drug conjugate (ADC) sacituzumab govitecan, a randomised study has been published that may represent a significant therapeutic advance. This review describes the latest developments in breast cancer subsequent to the ESMO Congress 2020.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据